David Davies

Dr. David Davies is a researcher at King's College London, focusing on advanced immunotherapeutic strategies, particularly Chimeric Antigen Receptor (CAR) T-cell engineering for cancer treatment. His work spans both preclinical and clinical domains, with emphasis on solid tumors (e.g., mesothelioma, head and neck carcinoma) and hematologic malignancies.

• Active research areas include CAR T-cell co-stimulation, targeted ErbB therapies, and modulating tumor microenvironments.
• Key collaborations involve KHP King's Health Partners and Asthma and Lung UK, with completed projects on gene-editing platforms and cytokine-neutralizing CAR therapies.
• His publications highlight innovations in CAR design, clinical trial analyses, and protocols for T-cell engineering.